Literature DB >> 15208521

Assessing and managing breast cancer risk: clinical tools for advising patients.

Bernard Friedenson1.   

Abstract

Using breast cancer risk assessment tools and going through the process of assessing breast cancer risk can answer many women's questions about what puts them at relatively higher or lower risk. This effectively engages both the clinician and the patient in a discussion about breast cancer, the chances of getting it, and the family's involvement--making the process as important as the actual tools. Examples of selected case histories demonstrate risk assessment using available tools such as the Gail-NCI and the Claus models. For some women, such as those considering tamoxifen or prophylactic surgeries, it may be desirable to prescreen for the inheritance of hereditary mutations and to follow with genetic testing, if indicated. Testing for mutations of breast cancer susceptibility genes or for their diminished expression adds to our ability to assess breast cancer risk at an individual level. The literature contains general interventions that are widely accepted to reduce the severity and the burden of breast cancer, and these are brought together here. The risk assessment process is an important part of a risk reduction program and can help motivate women to engage in prevention activities. This paper uses 2 hypothetical but fact-based and typical case histories to discuss the utility of risk assessment tools for informing women about their options.

Entities:  

Mesh:

Year:  2004        PMID: 15208521      PMCID: PMC1140711     

Source DB:  PubMed          Journal:  MedGenMed        ISSN: 1531-0132


  68 in total

1.  Oral contraceptives and the risk of breast cancer.

Authors:  Polly A Marchbanks; Jill A McDonald; Hoyt G Wilson; Suzanne G Folger; Michele G Mandel; Janet R Daling; Leslie Bernstein; Kathleen E Malone; Giske Ursin; Brian L Strom; Sandra A Norman; Phyllis A Wingo; Ronald T Burkman; Jesse A Berlin; Michael S Simon; Robert Spirtas; Linda K Weiss
Journal:  N Engl J Med       Date:  2002-06-27       Impact factor: 91.245

2.  Impact of gene patents on the cost-effective delivery of care: the case of BRCA1 genetic testing.

Authors:  Christine Sevilla; Claire Julian-Reynier; François Eisinger; Dominique Stoppa-Lyonnet; Brigitte Bressac-de Paillerets; Hagay Sobol; Jean-Paul Moatti
Journal:  Int J Technol Assess Health Care       Date:  2003       Impact factor: 2.188

3.  For patients, prediction of cancer risk can be worrisome.

Authors:  Christine Theisen
Journal:  J Natl Cancer Inst       Date:  2003-09-17       Impact factor: 13.506

4.  A breast cancer prediction model incorporating familial and personal risk factors.

Authors:  Jonathan Tyrer; Stephen W Duffy; Jack Cuzick
Journal:  Stat Med       Date:  2004-04-15       Impact factor: 2.373

5.  Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2.

Authors:  Mary-Claire King; Joan H Marks; Jessica B Mandell
Journal:  Science       Date:  2003-10-24       Impact factor: 47.728

6.  Recreational physical activity and the risk of breast cancer in postmenopausal women: the Women's Health Initiative Cohort Study.

Authors:  Anne McTiernan; Charles Kooperberg; Emily White; Sara Wilcox; Ralph Coates; Lucile L Adams-Campbell; Nancy Woods; Judith Ockene
Journal:  JAMA       Date:  2003-09-10       Impact factor: 56.272

Review 7.  Management of the high-risk patient.

Authors:  Victor G Vogel
Journal:  Surg Clin North Am       Date:  2003-08       Impact factor: 2.741

8.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial.

Authors:  Jacques E Rossouw; Garnet L Anderson; Ross L Prentice; Andrea Z LaCroix; Charles Kooperberg; Marcia L Stefanick; Rebecca D Jackson; Shirley A A Beresford; Barbara V Howard; Karen C Johnson; Jane Morley Kotchen; Judith Ockene
Journal:  JAMA       Date:  2002-07-17       Impact factor: 56.272

9.  Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women.

Authors:  T J Key; P N Appleby; G K Reeves; A Roddam; J F Dorgan; C Longcope; F Z Stanczyk; H E Stephenson; R T Falk; R Miller; A Schatzkin; D S Allen; I S Fentiman; T J Key; D Y Wang; M Dowsett; H V Thomas; S E Hankinson; P Toniolo; A Akhmedkhanov; K Koenig; R E Shore; A Zeleniuch-Jacquotte; F Berrino; P Muti; A Micheli; V Krogh; S Sieri; V Pala; E Venturelli; G Secreto; E Barrett-Connor; G A Laughlin; M Kabuto; S Akiba; R G Stevens; K Neriishi; C E Land; J A Cauley; L H Kuller; S R Cummings; K J Helzlsouer; A J Alberg; T L Bush; G W Comstock; G B Gordon; S R Miller; C Longcope
Journal:  J Natl Cancer Inst       Date:  2003-08-20       Impact factor: 13.506

10.  Evaluation of breast cancer risk assessment packages in the family history evaluation and screening programme.

Authors:  E Amir; D G Evans; A Shenton; F Lalloo; A Moran; C Boggis; M Wilson; A Howell
Journal:  J Med Genet       Date:  2003-11       Impact factor: 6.318

View more
  2 in total

Review 1.  Breast MR imaging in women at high-risk of breast cancer. Is something changing in early breast cancer detection?

Authors:  Francesco Sardanelli; Franca Podo
Journal:  Eur Radiol       Date:  2006-09-29       Impact factor: 5.315

2.  Developing a risk prediction model for breast cancer: a Statistical Utility to Determine Affinity of Neoplasm (SUDAN-CA Breast).

Authors:  Alaaddin M Salih; Dafallah M Alam-Elhuda; Musab M Alfaki; Adil E Yousif; Momin M Nouradyem
Journal:  Eur J Med Res       Date:  2017-09-29       Impact factor: 2.175

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.